Synergistic interaction of gabapentin with tiagabine in the hot-plate test in mice: An isobolographic analysis

Pharmacological Reports

Volumn 61, Issue 3, 2009, Pages 459-467

  Łuzczki, Jarogniew J ^a,b   Kołacz, Agnieszka ^a   Wojda, Ewa ^a   Czuczwar, Mirosław ^a   Przesmycki, Krzysztof ^a   Czuczwar, Stanisław J ^a,b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

Author keywords

Drug interaction; Gabapentin; Hot plate test; Isobolographic analysis; Maximum possible antinociceptive effect; Tiagabine

Indexed keywords

GABAPENTIN; NEUROTIN; TIAGABINE; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG POTENTIATION; EXPERIMENTAL STUDY; HOT PLATE TEST; LATENT PERIOD; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PAIN; PAIN THRESHOLD; THERMAL PAIN;

AMINES; ANIMALS; ANTICONVULSANTS; CYCLOHEXANECARBOXYLIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GAMMA-AMINOBUTYRIC ACID; MALE; MICE; MODELS, STATISTICAL; NIPECOTIC ACIDS; PAIN MEASUREMENT;

EID: 67651154283     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/s1734-1140(09)70087-8     Document Type: Article

References (45)

1. Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, LaMoteaux L, Garofalo E: Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA, 1998, 280, 1831-1836.
2. Berenbaum MC: What is synergy? Pharmacol Rev, 1989, 41, 93-141. Erratum in: Pharmacol Rev, 1989, 41, 422.
3. Caraceni A, Zecca E, Bonezzi C, Arcuri E, Yaya Tur R, Maltoni M, Visentin M et al.: Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. J Clin Oncol, 2004, 22, 2909-2917.
4. Chapman V, Suzuki R, Chamarette HL, Rygh U, Dickenson AH: Effects of systemic carbamazepine and gabapentin on spinal neuronal responses in spinal nerve ligated rats. Pain, 1998, 75, 261-272.
5. Chen SR, Pan HL: Effect of systemic and intrathecal gabapentin on allodyni a in a new rat model of postherpetic neuralgia. Brain Res, 2005, 1042, 108-113.
6. Cheng JK, Pan HL, Eisenach JC: Antiallodynic effect of intrathecal gabapentin and its interaction with clonidine in a rat model of postoperative pain. Anesthesiology, 2000, 92, 1126-1131.
7. Codd EE, Martinez RP, Molino L, Rogers KE, Stone DJ, Tallarida RJ: Tramadol and several anticonvulsants synergize in attenuating nerve injury-induced allodynia. Pain, 2008, 134, 254-262.
8. Czuczwar M, Kiś J, Luszczki J, Turski WA, Przesmycki K: Evaluation of interaction between gabapentin and baclofen in the formalin test in mice. Pol J Pharmacol, 2003, 55, 803-806.
9. Deckers CL, Czuczwar SJ, Hekster YA, Keyser A, Kubova H, Meinardi H, Patsalos PN et al.: Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia, 2000, 41, 1364-1374.
10. Di Trapani G, Mei D, Marra C, Mazza S, Capuano A: Gabapentin in the prophylaxis of migraine: a double-blind randomized placebo-controlled study. Clin Ther, 2000, 151, 145-148.
11. Donovan-Rodriguez T, Dickenson AH, Urch CE: Gabapentin normalizes spinal neuronal responses that correlate with behavior in a rat model of cancer-induced bone pain. Anesthesiology, 2005, 102, 132-140.
12. Eddy NB, Leimbach D: Synthetic analgesics. II. Dithienylbutenyl-and dithienylbutylamines. J Pharmacol Exp Ther, 1953, 107, 385-393.
13. Elia N, Lysakowski C, Tramer MR: Does multimodal analgesia with acetaminophen, nonsteroidal antiinflammatory drugs, or selective cyclooxygenase-2 inhibitors and patient-controlled analgesia morphine offer advantages over morphine alone? Meta-analyses of randomized trials. Anesthesiology, 2005, 103, 1296-1304.
14. Field MJ, Holloman EF, McCleary S, Hughes J, Singh L: Evaluation of gabapentin and S-(+)-3-isobutylgaba in a rat model of postoperative pain. J Pharmacol Exp Ther, 1997, 282, 1242-1246.
15. 2+ influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology, 2002, 42, 229-236.
16. Garry EM, Delaney A, Anderson HA, Sirinathsinghji EC, Clapp RH, Martin WJ, Kinchington PR et al.: Varicella zoster virus induces neuropathic changes in rat dorsal root ganglia and behavioral reflex sensitisation that is attenuated by gabapentin or sodium channel blocking drugs. Pain, 2005, 118, 97-111.
17. Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow R, Woodruff GN: The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem, 1996, 271, 5768-5776.
18. Greco WR, Bravo G, Parsons JC: The search for synergy: a critical review from a response surface perspective. Pharmacol Rev, 1995, 47, 331-385.
19. Ipponi A, Lamberti C, Medica A, Bartolini A, Malmberg- Aiello P: Tiagabine antinociception in rodents depends on GABA receptor activation: parallel antinociception testing and medial thalamus GABA microdialysis. Eur J Pharmacol, 1999, 368, 205-211.
20. Jin F, Chung F: Multimodal analgesia for postoperative pain control. J Clin Anesth, 2001, 13, 524-539.
21. Kroin JS, Buvanendran A, Cochran E, Tuman KJ: Characterization of pain and pharmacologic responses in an animal model of lumbar adhesive arachnoiditis. Spine, 2005, 30, 1828-1831.
22. Laughlin TM, Tram KV, Wilcox GL, Birnbaum AK: Comparison of antiepileptic drugs tiagabine, lamotrigine, and gabapentin in mouse models of acute, prolonged, and chronic nociception. J Pharmacol Exp Ther, 2002, 302, 1168-1175.
23. Loewe S: The problem of synergism and antagonism of combined drugs. Arzneimittelforschung, 1953, 3, 285-290.
24. Łuszczki JJ: Isobolographic analysis of interaction between drugs with nonparallel dose-response relationship curves: a practical application. Naunyn-Schmiedebergs Arch Pharmacol, 2007, 375, 105-114.
25. Łuszczki JJ, Czuczwar SJ: Dose-response relationship analysis of vigabatrin doses and their antinociceptive effects in the hot-plate test in mice. Pharmacol Rep, 2008, 60, 409-414.
26. Łuszczki JJ, Czuczwar SJ: Isobolographic profile of interactions between tiagabine and gabapentin: a preclinical study. Naunyn-Schmiedebergs Arch Pharmacol, 2004, 369, 434-446.
27. Łuszczki JJ, Kołacz A, Czuczwar M, Przesmycki K, Czuczwar SJ: Synergistic interaction of gabapentin with tiagabine in the formalin test in mice: An isobolographic analysis. Eur J Pain, 2008, doi:10.1016/ j.ejpain.2008. 08.002.
28. Łuszczki JJ, Ratnaraj N, Patsalos PN, Czuczwar SJ: Isobolographic analysis of interactions between loreclezole and conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Naunyn-Schmiedebergs Arch Pharmacol, 2006, 373, 169-181.
29. Łuszczki JJ, Swiader M, Parada-Turska J, Czuczwar SJ: Tiagabine synergistically interacts with gabapentin in the electroconvulsive threshold test in mice. Neuropsychopharmacology, 2003, 28, 1817-1830.
30. Meldrum BS, Chapman AG: Basic mechanisms of gabitril (tiagabine) and future potential developments. Epilepsia, 1999, 40, Suppl 9, S2-S6.
31. Motulsky HJ, Christopoulos A: Fitting models to biological data using linear and nonlinear regression. A practical guide to curve fitting. GraphPad Software Inc, San Diego, CA, USA, 2003.
32. Ng GY, Bertrand S, Sullivan R, Ethier N, Wang J, Yergey J, Belley M et al.: 2c-Aminobutyric acid type B receptors with specific heterodimer composition and post-synaptic actions in hippocampal neurons are targets of anticonvulsant gabapentin action. Mol Pharmacol, 2001, 59, 144-152.
33. Novak V, Kanard R, Kissel JT, Mendell JR: Treatment of painful sensory neuropathy with tiagabine: a pilot study. Clin Auton Res, 2001, 11, 357-361.
34. Pan HL, Eisenach JC, Chen SR: Gabapentin suppresses ectopic nerve discharges and reverses allodynia in neuropathic rats. J Pharmacol Exp Ther, 1999, 288, 1026-1030.
35. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L: Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA, 1998, 280, 1837-1842.
36. Schmauss C, Yaksh TL: In vivo studies on spinal opiate receptor systems mediating antinociception. II. Pharmacological profiles suggesting a differential association of mu, delta and kappa receptors with visceral chemical and cutaneous thermal stimuli in the rat. J Pharmacol Exp Ther, 1984, 228, 1-12.
37. Shannon HE, Eberle EL, Peters SC: Comparison of the effects of anticonvulsant drugs with diverse mechanisms of action in the formalin test in rats. Neuropharmacology, 2005, 48, 1012-1020.
38. Sist TC, Filadora VA, Miner M, Lema M: Experience with gabapentin for neuropathic pain in the head and neck: report of ten cases. Reg Anesth, 1997, 22, 473-478.
39. Solaro C, Tanganelli P: Tiagabine for treating painful tonic spasms in multiple sclerosis: a pilot study. J Neurol Neurosurg Psychiatry, 2004, 75, 341.
40. Surges R, Freiman TM, Feuerstein TJ: Gabapentin increases the hyperpolarization-activated cation current Ih in rat CA1 pyramidal cells. Epilepsia, 2003, 44, 150-156.
41. Suzdak PD, Jansen JA: A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia, 1995, 36, 612-626.
42. Swedberg MD: The mouse grid-shock analgesia test: pharmacological characterization of latency to vocalization threshold as an index of antinociception. J Pharmacol Exp Ther, 1994, 269, 1021-1028.
43. Tallarida RJ: Drug synergism and dose-effect data analysis. Chapman & Hall/CRC, Boca Raton, FL, USA, 2000.
44. Taylor CP, Gee NS, Su TZ, Kocsis JD, Welty DF, Brown JP, Dooley DJ et al.: A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res, 1998, 29, 233-249.
45. Todorov AA, Kolchev CB, Todorov AB: Tiagabine and gabapentin for the management of chronic pain. Clin J Pain, 2005, 21, 358-361.